University Of Toledo

University Of Toledo Health Science Campus Division operates as a recipient of federal grants in biomedical and clinical research, with no federal contract prime awards and no participation in federal contract vehicles. The division is a child entity of the University of Toledo, a state-controlled institution of higher learning headquartered in Toledo, Ohio, and competes exclusively in full-and-open federal grant competitions without set-aside designations.

The Health Science Campus Division's federal footprint is dominated by National Institutes of Health research grants in cancer, infectious disease, cardiovascular, aging, and neuroscience. Recent representative work includes a $768,796 National Institute of Allergy and Infectious Diseases grant (September 2026) to identify immunoprotective antigens for preventing Lyme disease through evaluation of attenuated bacterial mutants as vaccine candidates; a $418,822 National Cancer Institute award (May 2026) to develop selective allosteric modulators of the PTH1R receptor as inhibitors of prostate cancer bone metastases; and a $967,160 Defense Health Agency contract (August 2024) for development and delivery of the SAFE-T-NET virtual simulation platform to ensure operational readiness and sustainment of knowledge for military health personnel through multimodal assessment and on-demand virtual simulation. The division also received a $100,000 Office of Naval Research purchase order (March 2024) for a literature summary report on computational model software. A $6,831,000 National Institute of Standards and Technology grant (August 2023) funded expansion and renovation of the division's BSL-3 and animal research facilities, including three new biocontainment suites for Tier 1 select agent research and renovation of animal housing and procedure rooms.

Customer concentration sits heavily with the National Institutes of Health and its component institutes. NIH accounts for 64 awards across the division's recent footprint, with the National Cancer Institute placing 24 awards, the National Heart Lung and Blood Institute 17, the National Institute on Aging 17, and the National Institute of Allergy and Infectious Diseases 15. The Defense Health Agency is a secondary customer with 9 awards. The portfolio encompasses 42 distinct federal customer agencies. The division acts as a prime recipient on roughly 89 percent of awards and as a sub-recipient on approximately 11 percent, with sub-award roles documented under prime recipients including Brown University, Case Western Reserve University, Oklahoma Medical Research Foundation, Wayne State University, and Vanderbilt University Medical Center. Examples of sub-recipient work include participation in a Brown University cardiorenal aging interorgan communication study and collaboration with Cleveland Clinic Lerner College of Medicine on kidney transplant outcomes research.

Activity has remained moderate and volatile across the past five years—20 awards in 2022, declining to 12 in 2023, rebounding to 25 in 2024, then declining to 17 in 2025, with 7 awards recorded through September 2026. Twenty-three awards carry ultimate completion dates within the next twenty-four months and face recompete exposure. The division's research spans oncology (triple-negative breast cancer, prostate cancer metastasis, pancreatic cancer), infectious disease (Lyme disease, Borna virus polymerase structure, Klebsiella pneumoniae pathogenesis), cardiovascular and metabolic disease (hypertension, diabetic kidney disease, bile acid signaling), neuroscience and mental health (Alzheimer's disease kinome networks, PTSD cortical structure, adolescent anxiety and serotonin signaling), and environmental health (harmful algal bloom cyanotoxin exposure, pyrethroid pesticide developmental effects). The division also operates core research facilities including a flow cytometry core and BSL-3 biocontainment laboratory serving the broader university research community and supporting infectious disease research with national security implications.